ATE462433T1 - Methoden und pharmazeutische zusammensetzungen zur inhibition des tumorwachstums - Google Patents

Methoden und pharmazeutische zusammensetzungen zur inhibition des tumorwachstums

Info

Publication number
ATE462433T1
ATE462433T1 AT03078539T AT03078539T ATE462433T1 AT E462433 T1 ATE462433 T1 AT E462433T1 AT 03078539 T AT03078539 T AT 03078539T AT 03078539 T AT03078539 T AT 03078539T AT E462433 T1 ATE462433 T1 AT E462433T1
Authority
AT
Austria
Prior art keywords
agents
ppargamma
methods
pharmaceutical compositions
tumor growth
Prior art date
Application number
AT03078539T
Other languages
English (en)
Inventor
Bruce M Spiegelman
Soner Altiok
Elisabetta Mueller
Pasha Serraf
Peter Tontonoz
Original Assignee
Dana Farber Cancer Inst Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/923,346 external-priority patent/US6552055B2/en
Application filed by Dana Farber Cancer Inst Inc filed Critical Dana Farber Cancer Inst Inc
Application granted granted Critical
Publication of ATE462433T1 publication Critical patent/ATE462433T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT03078539T 1996-12-11 1997-12-11 Methoden und pharmazeutische zusammensetzungen zur inhibition des tumorwachstums ATE462433T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US76655396A 1996-12-11 1996-12-11
US08/923,346 US6552055B2 (en) 1996-12-11 1997-09-04 Methods and pharmaceutical compositions for inhibiting tumor cell growth

Publications (1)

Publication Number Publication Date
ATE462433T1 true ATE462433T1 (de) 2010-04-15

Family

ID=27117766

Family Applications (2)

Application Number Title Priority Date Filing Date
AT03078539T ATE462433T1 (de) 1996-12-11 1997-12-11 Methoden und pharmazeutische zusammensetzungen zur inhibition des tumorwachstums
AT97952407T ATE253903T1 (de) 1996-12-11 1997-12-11 Methoden und pharmazeutische zusammenstellungen zur wachstumsverhinderung von tumorzellen enthaltend einen ppar-gamma agonisten und einen map kinase inhibitor

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT97952407T ATE253903T1 (de) 1996-12-11 1997-12-11 Methoden und pharmazeutische zusammenstellungen zur wachstumsverhinderung von tumorzellen enthaltend einen ppar-gamma agonisten und einen map kinase inhibitor

Country Status (8)

Country Link
US (1) US7635708B2 (de)
EP (2) EP0948324B1 (de)
JP (2) JP4549443B2 (de)
AT (2) ATE462433T1 (de)
AU (1) AU5601898A (de)
CA (1) CA2274756C (de)
DE (2) DE69726182T2 (de)
WO (1) WO1998025598A2 (de)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998029120A1 (en) * 1996-12-31 1998-07-09 The Salk Institute For Biological Studies Treatment of liposarcomas using a combination of thiazolidinediones and retinoid x receptor selective agonists
US5814647A (en) 1997-03-04 1998-09-29 Board Of Regents, The University Of Texas System Use of troglitazone and related compounds for the treatment of the climacteric symptoms
FR2773075B1 (fr) * 1997-12-31 2000-05-05 Cird Galderma Utilisation d'activateurs de ppar-gamma en dermatologie
AU1707599A (en) * 1998-03-20 1999-10-18 Warner-Lambert Company Retinoid-glitazone combinations
US7045519B2 (en) 1998-06-19 2006-05-16 Chiron Corporation Inhibitors of glycogen synthase kinase 3
EP1143953A3 (de) * 1998-11-20 2002-02-06 Genentech, Inc. Verfahren zur hemmung der angiogenese
GB9908647D0 (en) * 1999-04-15 1999-06-09 Smithkline Beecham Plc Novel compounds
GB9917405D0 (en) * 1999-07-23 1999-09-22 Univ Dundee Methods of treatment and drug screening methods
WO2001052789A2 (en) 2000-01-20 2001-07-26 The Brigham And Women's Hospital, Inc. PAX8-PPARη NUCLEIC ACID MOLECULES AND POLYPEPTIDES AND USES THEREOF
NO20003591L (no) * 2000-07-13 2002-01-14 Thia Medica As Fettsyreanaloger for behandling av kreft
WO2002013864A1 (en) * 2000-08-16 2002-02-21 Sankyo Company, Limited Medicinal compositions for preventing and treating cancer
CA2419567A1 (en) 2000-09-01 2002-03-07 George Vande Woude Inhibition of mitogen-activated protein kinase (mapk) pathway: a selective therapeutic strategy against melanoma
WO2002080913A1 (en) * 2001-04-06 2002-10-17 F. Hoffmann-La Roche Ag Thiazolidinediones alone or in combination with other therapeutic agents for inhibiting or reducing tumour growth
US6756399B2 (en) 2001-06-29 2004-06-29 The United States Of America As Represented By The Department Of Health And Human Services Use of lipoxygenase inhibitors and PPAR ligands as anti-cancer therapeutic and intervention agents
US20040197834A1 (en) * 2001-07-20 2004-10-07 Francois Gervais Method to increase expression of pgd2 receptors and assays for identifying modulators of prostaglandin d2 receptors
WO2003032988A1 (fr) * 2001-10-17 2003-04-24 Sankyo Company, Limited Composition pharmaceutique
JP5249484B2 (ja) * 2001-12-11 2013-07-31 第一三共株式会社 医薬組成物
TW200300677A (en) * 2001-12-11 2003-06-16 Sankyo Co A pharmaceutical composition
AU2003220855A1 (en) * 2002-04-01 2003-10-13 Sankyo Company, Limited Medicinal antitumor composition
WO2004000356A1 (ja) * 2002-06-25 2003-12-31 Sankyo Company, Limited 利尿剤及びペルオキシソーム増殖因子活性化受容体（PPAR)γ活性化剤を含有する医薬組成物
JP2004083574A (ja) * 2002-06-25 2004-03-18 Sankyo Co Ltd 利尿剤及びペルオキシソーム増殖因子活性化受容体（ＰＰＡＲ）γ活性化剤を含有する医薬組成物
HU0301358D0 (en) 2003-05-14 2003-07-28 Debreceni Egyetem Novel use of ppargamma agonists
US8309562B2 (en) 2003-07-03 2012-11-13 Myrexis, Inc. Compounds and therapeutical use thereof
CN1984660B (zh) 2003-07-03 2010-12-15 美瑞德生物工程公司 作为天冬氨酸特异性半胱氨酸蛋白酶活化剂和细胞程序死亡诱导剂的4-芳基氨基-喹唑啉
JP2005200419A (ja) * 2004-01-16 2005-07-28 National Health Research Inst 癌治療法
JP4556511B2 (ja) * 2004-06-25 2010-10-06 ソニー株式会社 １５ｄ−ＰＧＪ２、及び、１５ｄ−ＰＧＪ２を用いた方法
US8258145B2 (en) 2005-01-03 2012-09-04 Myrexis, Inc. Method of treating brain cancer
EP1833482A4 (de) 2005-01-03 2011-02-16 Myriad Genetics Inc Verbindungen und ihre therapeutische verwendung
JP2006232754A (ja) * 2005-02-25 2006-09-07 Gi Biopolis:Kk 消化管粘膜切除後の消化管潰瘍治癒促進用スプレー剤
EP1858512A4 (de) * 2005-03-14 2009-08-05 Immunomedics Inc Verfahren zur krebsbehandlung mit ppar-gamma-antagonisten
EP1865954A4 (de) 2005-03-21 2010-12-15 Metabolex Inc Verfahren zur vermeidung von ödem bei der behandlung oder prävention von auf ppar gamma ansprechenden erkrankungen einschliesslich krebs
EP1937244B1 (de) 2005-09-30 2018-07-25 Io Therapeutics, LLC Behandlung von krebs mit spezifischen rxr-agonisten
WO2007061094A1 (ja) 2005-11-28 2007-05-31 Senju Pharmaceutical Co., Ltd. Ｐｐａｒアゴニスト含有医薬
JP5247686B2 (ja) 2007-05-21 2013-07-24 千寿製薬株式会社 ＰＰＡＲδアゴニスト含有医薬
WO2010070379A1 (en) * 2008-12-17 2010-06-24 Centre National De La Recherche Scientifique Rxr-ppargamma agonist/growth factor inhibitor combination therapy for inducing apoptosis and the treatment of cancer
CN103619168B (zh) 2011-06-29 2015-09-23 宾州研究基金会 用于治疗白血病的组合物、方法和药盒
US10653650B2 (en) 2011-12-13 2020-05-19 Io Therapeutics, Inc. Treatment of diseases by concurrently eliciting remyelination effects and immunomodulatory effects using selective RXR agonists
CN110151745A (zh) 2011-12-13 2019-08-23 Io治疗公司 使用rxr激动剂的自身免疫紊乱的治疗
JP5987175B2 (ja) * 2012-07-02 2016-09-07 学校法人福岡大学 乳癌，胃癌及び卵巣癌等に対する制癌剤
AU2013340478B2 (en) 2012-11-05 2018-08-23 Commissariat A L'energie Atomique Et Aux Energies Alternatives (Cea) Combination of an anti-cancer agent such as a tyrosinekinase inhibitor and a STAT5 antagonist, preferably a thiazolidinedione, for eliminating hematologic cancer stem cells in vivo and for preventing hematologic cancer relapse
EP3191095A2 (de) * 2014-09-08 2017-07-19 Dana Farber Cancer Institute, Inc. Verfahren zur krebsbehandlung mit verabreichung eines ppar-gamma-agonisten
WO2017075612A1 (en) * 2015-10-31 2017-05-04 Io Therapeutics, Inc. Treatment of cancer with combinations of rxr agonists and thyroid hormones
US9877941B2 (en) 2015-10-31 2018-01-30 Io Therapeutics, Inc. Treatment of nervous system disorders using combinations of RXR agonists and thyroid hormones
US10960013B2 (en) * 2016-03-04 2021-03-30 East Carolina University J-series prostaglandin-ethanolamides as novel therapeutics for skin and/or oral disorders
CN115252789A (zh) 2016-03-10 2022-11-01 Io治疗公司 Rxr激动剂和甲状腺激素在制备用于治疗自身免疫疾病的药物中的用途
US10835507B2 (en) 2016-03-10 2020-11-17 Io Therapeutics, Inc. Treatment of muscular disorders with combinations of RXR agonists and thyroid hormones
CA3076373A1 (en) 2017-09-20 2019-03-28 Io Therapeutics, Inc. Treatment of disease with esters of selective rxr agonists
US10966950B2 (en) 2019-06-11 2021-04-06 Io Therapeutics, Inc. Use of an RXR agonist in treating HER2+ cancers
WO2022054755A1 (ja) * 2020-09-08 2022-03-17 国立大学法人愛媛大学 蛍光色素剤及び腫瘍細胞の検出方法
KR20240119103A (ko) 2021-12-07 2024-08-06 아이오 테라퓨틱스, 인크. Her2+ 암 치료에서의 rxr 작용제 및 탁산의 용도
CA3242047A1 (en) 2021-12-07 2023-06-15 Io Therapeutics, Inc. Use of an rxr agonist in treating drug resistant her2+ cancers

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5071773A (en) * 1986-10-24 1991-12-10 The Salk Institute For Biological Studies Hormone receptor-related bioassays
US5605930A (en) * 1991-10-21 1997-02-25 The United States Of America As Represented By The Department Of Health And Human Services Compositions and methods for treating and preventing pathologies including cancer
ATE195716T1 (de) * 1992-04-22 2000-09-15 Ligand Pharm Inc Retinoid-x rezeptor selektive verbindungen
US5552271A (en) * 1992-06-16 1996-09-03 La Jolla Cancer Research Foundation RXR homodimer formation
US5466861A (en) * 1992-11-25 1995-11-14 Sri International Bridged bicyclic aromatic compounds and their use in modulating gene expression of retinoid receptors
HU224548B1 (hu) * 1993-04-07 2005-10-28 Taiho Pharmaceutical Co. Ltd. Tiazolidinszármazékok és ezeket tartalmazó gyógyszerkészítmények, valamint eljárás előállításukra
EP0724636A1 (de) 1993-10-22 1996-08-07 Ligand Pharmaceuticals, Inc. Menschlichen "peroxisomen proliferator" aktivierte rezeptor
WO1995018533A1 (en) 1994-01-04 1995-07-13 The Trustees Of The University Of Pennsylvania Methods and compounds affecting adipocyte differentiation and obesity
US5514821A (en) * 1994-05-27 1996-05-07 Ligand Pharmaceuticals Incorporated Ring-labeled retinoids and intermediates, and methods for their synthesis and use
US5594015A (en) * 1994-06-22 1997-01-14 Regents Of The University Of California Thiazolidine derivatives for the treatment of psoriasis
CA2194169A1 (en) 1994-07-01 1996-01-18 Ronald M. Evans Mammalian peroxisome proliferator-activated receptors and uses thereof
EP0769146A2 (de) 1994-07-01 1997-04-23 Ligand Pharmaceuticals, Inc. Screening von "nuc" inhibitoren
PL180048B1 (en) 1994-08-10 2000-12-29 Fhoffmann La Roche Ag Ligands of retinic acid x-receptors
US6022897A (en) * 1995-04-25 2000-02-08 The Salk Institute For Biological Studies Selective modulators of peroxisome proliferator activated receptor-gamma, and methods for the use thereof
JPH11511004A (ja) * 1995-05-04 1999-09-28 シティ・オブ・ホープ ヒト白血球１２−リポキシゲナーゼおよび疾病状態の病因でのその役割
US5939442A (en) * 1995-06-07 1999-08-17 The Salk Institute For Biological Studies Modulations of peroxisome proliferator activated receptor-γ, and methods for the use thereof
IL118778A (en) * 1995-07-03 1999-07-14 Sankyo Co Pharmaceutical compositions for the treatment of arteriosclerosis and xanthoma containing an hmg-coa reductase inhibitor
ES2216062T3 (es) * 1995-09-18 2004-10-16 Ligand Pharmaceuticals, Inc. Tratamiento de la niddm con agonistas del rxr.
WO1997017091A1 (en) * 1995-11-08 1997-05-15 University Of South Florida Guinea pig model for leiomyomas and atherosclerosis
US5814647A (en) * 1997-03-04 1998-09-29 Board Of Regents, The University Of Texas System Use of troglitazone and related compounds for the treatment of the climacteric symptoms

Also Published As

Publication number Publication date
JP4549443B2 (ja) 2010-09-22
CA2274756A1 (en) 1998-06-18
JP4550133B2 (ja) 2010-09-22
US7635708B2 (en) 2009-12-22
WO1998025598A3 (en) 1998-07-30
US20030144330A1 (en) 2003-07-31
DE69726182D1 (de) 2003-12-18
CA2274756C (en) 2007-03-13
DE69739828D1 (de) 2010-05-12
WO1998025598A2 (en) 1998-06-18
AU5601898A (en) 1998-07-03
JP2001510462A (ja) 2001-07-31
EP0948324A2 (de) 1999-10-13
ATE253903T1 (de) 2003-11-15
JP2009063566A (ja) 2009-03-26
EP1410799A1 (de) 2004-04-21
EP1410799B1 (de) 2010-03-31
DE69726182T2 (de) 2004-08-12
EP0948324B1 (de) 2003-11-12

Similar Documents

Publication Publication Date Title
ATE462433T1 (de) Methoden und pharmazeutische zusammensetzungen zur inhibition des tumorwachstums
MY136037A (en) Biphenyl pyrimidone lp-pla2 inhibitors
BR9709015A (pt) Quinolina carboxamidas como inbidores de tnf e como inbidores de pde-iv
DE3789053D1 (de) Vorrichtung zur Behandlung von Hypertrophie der Vorsteherdrüse.
DE69830072D1 (de) Radioaktive zusammensetzungen zur behandlung von prostatatumoren
ATE308880T1 (de) Verfahren zur erhöhung der biologischen effektivität von zusammensetzungen zur pflanzenbehandlung
EP0986382A4 (de) Raf kinase hemmer
DE69937646D1 (de) vORRICHTUNG ZUR BEHANDLUNG DER HARNINKONTINENZ
DE59903921D1 (de) Indolderivate und deren verwendung zur behandlung von malignen und anderen, auf pathologischen zellproliferationen beruhenden erkrankungen
BR9814361A (pt) Inibição de quinase raf usando uréiasheterocìclicas substituìdas por arila eheteroarila
DE69916035D1 (de) Vorrichtung zur behandlung von halbleiterscheiben
PT1233958E (pt) Inibidores de histona desacetilase
DE3674308D1 (de) Biozide zusammensetzungund verfahren zur behandlung von wasser.
DE3675792D1 (de) Vorrichtung zur behandlung von bohrloechern.
ATE418999T1 (de) Verfahren zur behandlung von multiplem myelom und von myelom- induzierter knochenresorption mit antagonisten der integrin-/rezeptorbindung
AR024138A1 (es) Inhibidores de la proliferacion celular
ATE292801T1 (de) Verfahren zum screening von inhibitoren von asp2
NO20010956D0 (no) Modulering av hukommelseseffektor T-celler samt midler for dette
IS1407B6 (is) Útbúnaður til að nema burtu yfirborð af vöðvavef dýra, einkum fiskflaka
DE3581703D1 (de) Verfahren und vorrichtung zur biologischen behandlung von wasser, insbesondere zur denitrifikation von rohwasser zur trinkwasseraufbereitung.
NO20003848D0 (no) FremgangsmÕte ved behandling av folikkulært lymfom ved anvendelse av inhibitorer for lymfotoksin (LT)-veien
DE69932342D1 (de) Verfahren und zusammensetzungen zur hemmung von neoplastischem zellwachstums
BR9815617A (pt) Compostos substituìdos de 11-fenil-dibenzazepina, composição farmacêutica baseada nos referidos compostos, e métodos para inibir a proliferação de células de mamìferos e para tratamento ou prevenção de desordem causada por proliferação anormal de células
ATA344985A (de) Vorrichtung zur behandlung von gewaesserablagerungen
WO2003030825A3 (en) CCAAT/ENHANCER BINDING PROTEIN-β (C/EBPβ IS A MOLECULAR TARGET FOR CANCER TREATMENT

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties